FMS-like tyrosine kinase 3 (FLT3) is commonly activated in acute myeloid leukemia and is linked to poor patient outcomes.
Three specific short hairpin RNAs (FLT3-shRNAs) were designed to silence FLT3 in THP-1 leukemia cells, with shRNA1 showing the strongest inhibition.
After 72 hours of treatment with shRNA1, FLT3 mRNA and protein levels were significantly reduced, indicating its potential for future research on FLT3-targeted therapies.